CereneBERKELEY, Calif. — (November 20, 2025) — Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, MBA, CPA, as Chief Financial Officer.
Mr. Brown is a seasoned financial executive with deep expertise in strategic finance, operations, and growth planning for healthcare and medtech organizations. As an MBA and CPA, he brings the combination of strong financial acumen, regulatory rigor, and business leadership needed to guide high-growth companies in regulated industries.
Before joining Channel, Mr. Brown held senior financial roles across medtech and life sciences firms, where he built scalable financial infrastructure, led fundraising and M&A efforts, and aligned financial operations with commercialization goals.
“We’re thrilled to bring Robert on board,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “His credentials and track record in financial leadership will be invaluable as we scale our operations and expand access to the Cerene® Cryotherapy Device.”
“I am honored to join Channel Medsystems at such a transformative moment,” said Robert Brown, MBA, CPA. “I believe deeply in Channel Medsystem’s mission to transform women’s healthcare. I look forward to supporting growth, strengthening financial operations, and helping advance broader access to safe and effective therapies.” With Mr. Brown’s appointment, Channel Medsystems strengthens its executive team’s financial leadership to support sustained growth and strategic execution.
About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care.
For more information, please visit www.cerene.com and follow us on LinkedIn.
Media Contact:
Tara Murphy
Vice President, Marketing
tmurphy@cerene.com
215-620-3004
Important Safety Information
Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include cramping, nausea, vomiting, vaginal discharge and spotting. For detailed benefit and risk information, consult the Cerene Instructions for use (IFU) or your healthcare professional. Learn More
